Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Wahid Hanna"'
Autor:
Bayard L. Powell, Kieron Dunleavy, Michelle A. Fanale, Philip J. Bierman, David Peace, Andrea Nicole Lucas, Jeremy S. Abramson, Wyndham H. Wilson, Christopher Melani, Stefania Pittaluga, Peter R. Watson, Seth M. Steinberg, Wahid Hanna, Brad S. Kahl, Elaine S. Jaffe, Mark Roschewski, Brian K. Link, Nancy L. Bartlett, Richard F. Little, Ariela Noy, Deepa Jagadeesh, Jonathan W. Friedberg, Prapti A. Patel, Ronald T. Mitsuyasu
Publikováno v:
J Clin Oncol
PURPOSE Burkitt lymphoma is an aggressive B-cell lymphoma curable with dose-intensive chemotherapy derived from pediatric leukemia regimens. Treatment is acutely toxic with late sequelae. We hypothesized that dose-adjusted etoposide, doxorubicin, cyc
Autor:
Zhao Yang, Rajesh K. Malik, Janakiraman Subramanian, Lowell L. Hart, Raid Aljumaily, David R. Spigel, Renata Ferrarotto, Misha L. Johnson, Wahid Hanna, Dragana Jovanovic, Z. Andric, Maen A. Hussein, Taofeek K. Owonikoko, Bojan Zaric, Krishna Kishore Pachipala, J. Thaddeus Beck, Shannon R. Morris, Steven Adler, Miroslav Samarzija, Davorin Radosavljevic
Publikováno v:
Journal of Clinical Oncology. 37:8505-8505
8505 Background: Multi-lineage myelosuppression is an acute toxicity of cytotoxic chemotherapy leading to hematologic adverse events and dose reductions and delays. Current therapies are lineage specific and administered after chemotherapy damage.Tri
Autor:
Tanios Bekaii-Saab, Wahid Hanna, Laura Borodyansky, Sameh Mikhail, Alexander Starodub, Yue Chang, Cindy Oh, Wei Li, Xiaoshu Dai, Walid L. Shaib, Safi Shahda, Chiang Li, Anterpreet S. Neki, Anne M. Noonan, Bert H. O'Neil, Bassel F. El-Rayes, Emily Brooks
Publikováno v:
Journal of Clinical Oncology. 36:4110-4110
4110Background: NAPA is an oral investigational agent, hypothesized to inhibit cancer stemness pathways, including STAT3 pathway implicated in cancer stem-cell viability. We report updated data in ...
Autor:
Alexander Starodub, Amikar Sehdev, Chiang Li, Walid L. Shaib, Wahid Hanna, Kristen K. Ciombor, Laura Borodyansky, Sameh Mikhail, Bassel F. El-Rayes, Wei Li, Safi Shahda, Youzhi Li, Anterpreet S. Neki, Tanios Bekaii-Saab, Cindy Oh, Anne M. Noonan, Bert H. O'Neil
Publikováno v:
Journal of Clinical Oncology. 35:4106-4106
4106 Background: Cancer stem cells are fundamentally important for resistance to therapy, recurrence and metastasis. Napabucasin is a first-in-class cancer stemness inhibitor in development identified by its ability to inhibit STAT3-driven gene trans
Autor:
Chiang Li, Yuan Gao, Adrian Langleben, Wahid Hanna, Matthew Hitron, Stephen Lane Richey, Carlos Becerra, Scott A. Laurie, Youzhi Li, Wei Li, Gregory M. Cote
Publikováno v:
Journal of Clinical Oncology. 35:9052-9052
9052 Background: Napabucasin is a first-in-class cancer stemness inhibitor, identified by its ability to inhibit STAT3-driven gene transcription and spherogenesis of cancer stem cells (Li et al PNAS 112 (6):1839, 2015). Napabucasin has shown potent s
Autor:
Carlos Becerra, Youzhi Li, Wahid Hanna, Chiang Li, Kimiko Kossler, Stephanie Hume, Paul Conkling, Stephen Lane Richey, William Jeffery Edenfield, Gregory M. Cote, Matthew Hitron, Alexander I. Spira, Adrian Langleben, Scott A. Laurie, Rebecca S. Heist
Publikováno v:
Journal of Clinical Oncology. 34:9093-9093
9093Background: Napabucasin (BBI-608, BB608) is a first-in-class cancer stemness inhibitor that works through inhibiting the STAT3 pathway, and it has shown potent synergistic anti-tumor activity w...
Autor:
Wei Li, Safi Shahda, Tanios Bekaii-Saab, Wahid Hanna, Walid L. Shaib, Cindy Oh, Youzhi Li, Alexander Starodub, Chiang Li, Bert H. O'Neil, Laura Borodyansky, Bassel F. El-Rayes
Publikováno v:
Journal of Clinical Oncology. 34:4128-4128
4128Background: BB608 (aka napabucasin, BBI-608) is an oral first-in-class cancer stemness inhibitor that works by targeting Stat3-driven gene transcription. Preclinical anti-tumor activity was obs...
Autor:
Alexander Starodub, Safi Shahda, Chiang Li, Bert H. O'Neil, Laura Borodyansky, Wahid Hanna, Bassel F. El-Rayes, Tanios Bekaii-Saab, Cindy Oh
Publikováno v:
Journal of Clinical Oncology. 34:284-284
284 Background: BBI-608 is an oral first-in-class cancer stemness inhibitor that works by blocking STAT3-mediated transcription of cancer stemness genes. Potent anti-CSC activity was observed in vitro and in vivo, in mono- and combination therapy. In